RP 60556A

Drug Profile

RP 60556A

Alternative Names: NXL-102

Latest Information Update: 17 Aug 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Class Antibacterials; Naphthyridines; Piperazines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 17 Aug 2007 Discontinued - Preclinical for Gram-positive infections in France (Topical)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 07 Jan 2002 An in vitro study has been added to the Bacterial Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top